Eisai Co, Biogen Inc.’s Alzheimer’s drug gets EU’s marketing approval
HQ Team April 16, 2025: Eisai Co., Ltd. and Biogen Inc.’s drug to treat Alzheimer’s disease got marketing authorisation in the European Union,.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team April 16, 2025: Eisai Co., Ltd. and Biogen Inc.’s drug to treat Alzheimer’s disease got marketing authorisation in the European Union,.
HQ Team March 21, 2025: A study from China adds to mounting evidence that semaglutide—a medication widely used for type 2 diabetes (Ozempic).
HQ Team March 4, 2025: Tau proteins in brain neurons can form neurofibrillary tangles, which are a hallmark of Alzheimer’s disease, and these.
Ireland’s Medtronic Plc’s deep brain stimulation device for patients with Parkinson’s disease has been approved by the US Food and Drug Administration, according.
Researchers at Cambridge are developing implants that could help repair damaged brain cells and treat diseases like Parkinson’s.
HQ Team January 21, 2024: The popular diabetes drugs, glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic, have gained immense popularity for their.
Biogen Inc., plans to buy all outstanding shares totalling 61.17 million of Sage Therapeutics Inc., for $7.22 a share, representing a premium of.
HQ Team December 28, 2024: Research has shown a potential connection between the progression of Alzheimer’s disease in people who take sleeping pills..
HQ Team December 18, 2024: Taxi and ambulance drivers may have a lower risk of dying from Alzheimer’s disease compared to many other.
HQ Team December 12, 2024: Filamon Limited, an Australian biotech company, has announced a significant advancement in dementia treatment with its new drug,.